{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:05:19Z","timestamp":1792123519752,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11894-025-01028-9","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:42:10Z","timestamp":1764852130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD19 CAR-T Cell Therapy for Relapsed or Refractory Nodal and Gastrointestinal Follicular Lymphoma: Current Advances and Future Perspectives"],"prefix":"10.1007","volume":"27","author":[{"given":"Takuya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1028_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","volume":"23","author":"G Salles","year":"2022","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E, et al. Tisagenlecleucel in relapsed or refractory follicular lymphoma (ELARA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2022;23:91\u2013103.","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"1028_CR2","first-page":"7508","volume":"39","author":"NH Fowler","year":"2021","unstructured":"Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: primary analysis of the phase 2 ELARA trial. J Clin Oncol. 2021;39(suppl 15):7508.","journal-title":"J Clin Oncol"},{"key":"1028_CR3","first-page":"456","volume":"10","author":"C Jacobson","year":"2025","unstructured":"Jacobson C, Chavez JC, Sehgal AR, et al. Lisocabtagene Maraleucel for patients with relapsed or refractory follicular lymphoma (TRANSCEND FL): a multicentre, seamless, phase 1\/2 study. Lancet Haematol. 2025;10:456\u201367.","journal-title":"Lancet Haematol"},{"key":"1028_CR4","first-page":"1024","volume":"31","author":"J Wang","year":"2025","unstructured":"Wang J, Rivas MA, Chen H, et al. Predictive biomarkers of T-cell exhaustion and response to CD19 CAR T-cell therapy in indolent lymphomas. Nat Med. 2025;31:1024\u201336.","journal-title":"Nat Med"},{"key":"1028_CR5","first-page":"612","volume":"24","author":"VE Kennedy","year":"2025","unstructured":"Kennedy VE, Borrello I, June CH. Off-the-shelf CAR-T therapies: current landscape and future prospects. Nat Rev Drug Discov. 2025;24:612\u201330.","journal-title":"Nat Rev Drug Discov"},{"key":"1028_CR6","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: refueling the CAR. Blood. 2017;129:1039\u201341.","journal-title":"Blood"},{"issue":"suppl 1","key":"1028_CR7","first-page":"232","volume":"140","author":"SJ Schuster","year":"2022","unstructured":"Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: updated results from the ELARA trial. Blood. 2022;140(suppl 1):232\u20134.","journal-title":"Blood"},{"key":"1028_CR8","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377:2545\u201354.","journal-title":"N Engl J Med"},{"key":"1028_CR9","first-page":"50","volume":"66","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Turtle CJ. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med. 2018;66:50\u20132.","journal-title":"Curr Res Transl Med"},{"key":"1028_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"1028_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20:31\u201342.","journal-title":"Lancet Oncol"},{"key":"1028_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, et al. Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy. Blood. 2018;131:121\u201330.","journal-title":"Blood"},{"key":"1028_CR13","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"1028_CR14","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR\u2013T cells of defined CD4+:CD8\u2009+\u2009composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123\u201338.","journal-title":"J Clin Invest"},{"key":"1028_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1028_CR16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene Maraleucel for relapsed\/refractory large B-cell lymphoma (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"issue":"suppl 1","key":"1028_CR17","first-page":"236","volume":"140","author":"JS Abramson","year":"2022","unstructured":"Abramson JS, Siddiqi T, Palomba ML, et al. High durable complete response (CR) rates in patients with relapsed\/refractory follicular lymphoma treated with lisocabtagene Maraleucel (liso-cel) in TRANSCEND FL. Blood. 2022;140(suppl 1):236\u20138.","journal-title":"Blood"},{"issue":"suppl 1","key":"1028_CR18","first-page":"148","volume":"41","author":"NH Fowler","year":"2023","unstructured":"Fowler NH, Dickinson MJ, Dreyling M, et al. Tisagenlecleucel in follicular lymphoma: updated analysis of ELARA trial. Hematol Oncol. 2023;41(suppl 1):148\u20139.","journal-title":"Hematol Oncol"},{"key":"1028_CR19","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.3390\/cancers15133501","volume":"15","author":"S Chocarro","year":"2023","unstructured":"Chocarro S, Ruiz de Sabando R, Montalban-Bravo G, et al. Current immunotherapeutic approaches in follicular lymphoma. Cancers (Basel). 2023;15:3501.","journal-title":"Cancers (Basel)"},{"issue":"suppl 16","key":"1028_CR20","first-page":"7512","volume":"41","author":"G Salles","year":"2023","unstructured":"Salles G, Casulo C, Barr PM, et al. Epcoritamab, a CD3xCD20 bispecific antibody, in patients with relapsed or refractory follicular lymphoma: updated results from EPCORE NHL-2. J Clin Oncol. 2023;41(suppl 16):7512.","journal-title":"J Clin Oncol"},{"key":"1028_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar MJ, et al. Mosunetuzumab in patients with relapsed or refractory follicular lymphoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"1028_CR22","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","volume":"9","author":"R Bannerji","year":"2022","unstructured":"Bannerji R, Allan JN, Arnason JE, et al. Odronextamab, a human CD20\u00d7CD3 bispecific antibody, for patients with relapsed or refractory B-cell non-Hodgkin lymphoma: results from a phase 1 study. Lancet Haematol. 2022;9:e327\u201339.","journal-title":"Lancet Haematol"},{"key":"1028_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379:934\u201347.","journal-title":"N Engl J Med"},{"key":"1028_CR24","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"Leonard JP, Trneny M, Izutsu K, et al. AUGMENT: a phase 3 study of Lenalidomide plus rituximab versus placebo plus rituximab in relapsed\/refractory indolent lymphoma. J Clin Oncol. 2019;37:1188\u201399.","journal-title":"J Clin Oncol"},{"key":"1028_CR25","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1200\/JCO.2013.51.5890","volume":"32","author":"JM Tuscano","year":"2014","unstructured":"Tuscano JM, Dutia M, Link BK, et al. A phase II study of Lenalidomide combined with rituximab in patients with previously untreated follicular lymphoma. J Clin Oncol. 2014;32:2067\u201373.","journal-title":"J Clin Oncol"},{"key":"1028_CR26","first-page":"2626","volume":"106","author":"TE Witzig","year":"2021","unstructured":"Witzig TE, Tam CS, Olszewski AJ, et al. Acalabrutinib, a selective Bruton tyrosine kinase inhibitor, in relapsed\/refractory follicular lymphoma. Haematologica. 2021;106:2626\u201334.","journal-title":"Haematologica"},{"key":"1028_CR27","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1200\/JCO.2022.40.16_suppl.7572","volume":"40","author":"CL Batlevi","year":"2022","unstructured":"Batlevi CL, Salles G, de Vos S, et al. Parsaclisib monotherapy in relapsed\/refractory follicular lymphoma: results of the CITADEL-203 study. J Clin Oncol. 2022;40:3620\u20139.","journal-title":"J Clin Oncol"},{"key":"1028_CR28","first-page":"594","volume":"15","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Davids MS. Bcl-2 inhibition in chronic lymphocytic leukemia and other B-cell malignancies. Clin Adv Hematol Oncol. 2017;15:594\u2013606.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1028_CR29","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","volume":"15","author":"MS Davids","year":"2022","unstructured":"Davids MS, Kim HT, Bachireddy P, et al. First-in-human phase I study of venetoclax in patients with relapsed\/refractory non-Hodgkin lymphoma. J Hematol Oncol. 2022;15:142.","journal-title":"J Hematol Oncol"},{"key":"1028_CR30","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","volume":"21","author":"F Morschhauser","year":"2020","unstructured":"Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for relapsed or refractory follicular lymphoma: primary analysis of an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol. 2020;21:1433\u201342.","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"1028_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2020-137681","volume":"136","author":"P Martin","year":"2020","unstructured":"Martin P, Bartlett NL, Chen AI, et al. A phase 1 study of CPI-0610, a selective EZH2 inhibitor, in patients with relapsed or refractory lymphomas. Blood. 2020;136(suppl 1):7\u20138.","journal-title":"Blood"},{"key":"1028_CR32","first-page":"2446","volume":"132","author":"PL Zinzani","year":"2018","unstructured":"Zinzani PL, Flinn IW, Tam CS, et al. Duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma. Blood. 2018;132:2446\u201355.","journal-title":"Blood"},{"key":"1028_CR33","first-page":"845","volume":"100","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Reeder CB, Han JJ, et al. Everolimus for relapsed\/refractory indolent non-Hodgkin lymphoma: final results of a phase II trial. Haematologica. 2015;100:845\u201353.","journal-title":"Haematologica"},{"key":"1028_CR34","first-page":"456","volume":"10","author":"CA Jacobson","year":"2025","unstructured":"Jacobson CA, Chavez JC, Sehgal AR, et al. Lisocabtagene Maraleucel for patients with relapsed or refractory follicular lymphoma (TRANSCEND-FL): a multicentre, seamless, phase 1\/2 study. Lancet Haematol. 2025;10:456\u201367.","journal-title":"Lancet Haematol"},{"key":"1028_CR35","first-page":"2512","volume":"9","author":"AK Singh","year":"2025","unstructured":"Singh AK, Khatri R, Johnson LL, et al. Optimization of ex vivo expansion and manufacturing of CD19 CAR T cells: real-world lessons from a phase 2 multicenter trial. Blood Adv. 2025;9:2512\u201321.","journal-title":"Blood Adv"},{"key":"1028_CR36","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.3748\/wjg.v29.i48.6179","volume":"29","author":"T Watanabe","year":"2023","unstructured":"Watanabe T. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas. World J Gastroenterol. 2023;29:6179\u201397.","journal-title":"World J Gastroenterol"},{"key":"1028_CR37","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3748\/wjg.v29.i23.3574","volume":"29","author":"T Watanabe","year":"2023","unstructured":"Watanabe T. Recent advances in treatment of nodal and gastrointestinal follicular lymphoma. World J Gastroenterol. 2023;29:3574\u201394.","journal-title":"World J Gastroenterol"},{"key":"1028_CR38","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v16.i44.5543","volume":"16","author":"T Watanabe","year":"2010","unstructured":"Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: current status and future development. World J Gastroenterol. 2010;16:5543\u201354.","journal-title":"World J Gastroenterol"},{"key":"1028_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01842-z","volume":"9","author":"T Watanabe","year":"2024","unstructured":"Watanabe T. Recent advances in treatment of follicular lymphoma: efficacy of PI3K\u03b1\/\u03b4 inhibitor (TQ-B3525). Signal Transduct Target Ther. 2024;9:134.","journal-title":"Signal Transduct Target Ther"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-025-01028-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-025-01028-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:03:17Z","timestamp":1772578997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-025-01028-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s11894-025-01028-9","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}